Crystalline Form C of Neuroactive Steroid for Stable Oral Dosage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing NMDA receptor positive allosteric modulators face challenges in achieving an appropriate balance of characteristics such as affinity, activity duration, oral bioavailability, tissue distribution, and stability, which are crucial for effective therapeutic use in solid dosage forms.
Innovation Solution
Development of a crystalline form of Compound 1, specifically Form C, characterized by distinct XRPD peaks and thermal stability, which can be used in solid dosage forms to address these challenges.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a positive allosteric modulator is developed for NMDA receptors, then therapeutic efficacy is improved, but achieving appropriate balance of multiple characteristics (affinity, activity duration, oral bioavailability, tissue distribution, and stability) becomes complex and challenging
Solution Approach 1:
The patent applies parameter changes by developing different crystalline forms (polymorphs) of Compound 1, each with distinct physical properties. Form C specifically was selected and optimized to achieve the appropriate balance of characteristics including stability, solubility, and bioavailability. By changing the physical state and crystalline structure parameters, the patent resolves the complexity of balancing multiple characteristics while maintaining therapeutic efficacy.
Solution Approach 2:
The patent creates a composite pharmaceutical formulation by combining crystalline Form C of Compound 1 with pharmaceutically acceptable carriers and excipients. This composite approach allows optimization of multiple characteristics simultaneously - the crystalline form provides stability and defined solubility, while the carrier system enables appropriate bioavailability and tissue distribution, resolving the complexity of balancing multiple characteristics.
2Productivity
If solid dosage forms are prepared for commercial preparation, then manufacturing scalability is improved, but challenges arise in maintaining appropriate properties (chemical stability, thermal stability, solubility, hygroscopicity, particle size, yield, impurity content, drying properties, milling properties, and stability during tableting)
Solution Approach 1:
The patent resolves manufacturing challenges by identifying and optimizing specific parameters of crystalline Form C, including its differential scanning calorimetry (DSC) thermogram showing an endothermic peak at about 204°C, X-ray powder diffraction (XRPD) pattern with characteristic peaks, and other physical properties. These defined parameters enable consistent manufacturing across scale while maintaining all required properties.
Solution Approach 2:
The patent applies preliminary action by pre-characterizing and selecting crystalline Form C with optimal properties before manufacturing. The form was screened and selected based on preliminary evaluation of stability, solubility, and other critical properties, ensuring that subsequent manufacturing processes can proceed with controlled and predictable outcomes for all physical properties.
3Stability of the object's composition
If chemical stability and thermal stability are improved through crystalline form selection, then shelf life is extended, but solubility and bioavailability may be compromised
Solution Approach 1:
The patent resolves this contradiction by optimizing the crystalline structure parameters of Form C to achieve an optimal balance. The form exhibits defined DSC and XRPD characteristics that indicate appropriate packing density and intermolecular interactions, providing enhanced stability while maintaining adequate solubility through controlled crystal lattice energy and surface properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Form C provides improved efficacy, safety, and manufacturing properties, enabling effective treatment of CNS-related conditions and induction of sedation or anesthesia.
Implementation Method 1
crystalline Form C, wherein Form C is characterized by an XRPD pattern comprising peaks at 12.0±0.2, 15.1±0.2, and 21.3±0.2 degrees 2θ
Implementation Method 2
the DSC thermogram comprises an endothermic peak at about 204° C.
Data Source
AI summary
The disclosure relates to a crystalline solid form of Compound 1. The disclosure also provides methods of preparing said crystalline solid form of Compound 1.